This was the final project (April 2015) from my Data Analytics course from Wayne State University. This presentation discuss diseases that share the breast cancer gene based on data gathered from DisGeNet (disease and gene association database).
The document discusses a potential collaboration between LifeArc and Biocartis to develop a circulating tumor ESR1 Mutation Test using Biocartis' Idylla platform. The test would detect mutations in the ESR1 gene indicative of resistance to endocrine hormone therapy in metastatic breast cancer. LifeArc has expertise in diagnostic development and Biocartis has an automated molecular testing platform. The test could help guide treatment decisions for breast cancer patients by monitoring their risk of resistance to hormone therapies.
Advancing The Prevention And Cure Of Cancerfondas vakalis
The document discusses the shared missions and collaborations between the American Association for Cancer Research (AACR) and the National Cancer Institute (NCI) to advance cancer research and reduce the burden of cancer. It outlines their joint efforts in conferences, workshops, and think tanks. It also summarizes advances in cancer prevention, early detection, and treatment that have contributed to reduced cancer mortality rates in recent years but challenges remain.
Breast Cancer, Ovarian Cancer and Prostate CancerThet Su Win
This document discusses hereditary breast, ovarian, and prostate cancer. It provides information on BRCA1 and BRCA2 mutations which are responsible for a large portion of familial breast cancer cases. Other genes like PALB2 are also discussed. The document reports the results of a study that sequenced DNA from breast cancer patients and found PALB2 mutations in 1% of cases negative for BRCA1/2 mutations, suggesting PALB2 mutations also contribute to hereditary breast cancer risk.
A data driven nomogram for breast cancer survivalLisa Federer
This document describes the development of a nomogram to predict breast cancer survival using demographic, diagnostic, and treatment data from the SEER database. The authors selected 13 variables related to survival time, age, race, cancer stage and other factors. Different classification models were tested including logistic regression, naive bayes, decision trees, and random forests. Cox proportional hazards and Aalen's additive regression models were also used. The results were used to build a "calculator" or nomogram to estimate survival time for individuals based on their characteristics. Limitations include the nomogram not being a substitute for medical advice and potential missing or incomplete data in the SEER database.
The document discusses a potential collaboration between LifeArc and Biocartis to develop a circulating tumor ESR1 Mutation Test using Biocartis' Idylla platform. The test would detect mutations in the ESR1 gene indicative of resistance to endocrine hormone therapy in metastatic breast cancer. LifeArc has expertise in diagnostic development and Biocartis has an automated molecular testing platform. The test could help guide treatment decisions for breast cancer patients by monitoring their risk of resistance to hormone therapies.
Advancing The Prevention And Cure Of Cancerfondas vakalis
The document discusses the shared missions and collaborations between the American Association for Cancer Research (AACR) and the National Cancer Institute (NCI) to advance cancer research and reduce the burden of cancer. It outlines their joint efforts in conferences, workshops, and think tanks. It also summarizes advances in cancer prevention, early detection, and treatment that have contributed to reduced cancer mortality rates in recent years but challenges remain.
Breast Cancer, Ovarian Cancer and Prostate CancerThet Su Win
This document discusses hereditary breast, ovarian, and prostate cancer. It provides information on BRCA1 and BRCA2 mutations which are responsible for a large portion of familial breast cancer cases. Other genes like PALB2 are also discussed. The document reports the results of a study that sequenced DNA from breast cancer patients and found PALB2 mutations in 1% of cases negative for BRCA1/2 mutations, suggesting PALB2 mutations also contribute to hereditary breast cancer risk.
A data driven nomogram for breast cancer survivalLisa Federer
This document describes the development of a nomogram to predict breast cancer survival using demographic, diagnostic, and treatment data from the SEER database. The authors selected 13 variables related to survival time, age, race, cancer stage and other factors. Different classification models were tested including logistic regression, naive bayes, decision trees, and random forests. Cox proportional hazards and Aalen's additive regression models were also used. The results were used to build a "calculator" or nomogram to estimate survival time for individuals based on their characteristics. Limitations include the nomogram not being a substitute for medical advice and potential missing or incomplete data in the SEER database.
Alterations of the genes involved in the PI3K and estrogen-receptor pathways ...Enrique Moreno Gonzalez
Chemotherapy with trastuzumab is widely used for patients with human epidermal growth
factor receptor 2-positive (HER2+) breast cancer, but a significant number of patients with
the tumor fail to respond, or relapse. The mechanisms of recurrence and biomarkers that indicate the response to the chemotherapy and outcome are not fully investigated.
Us breast cancer therapy market opportunity analysisKuicK Research
"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:
US Breast Cancer Incidence & Prevalence
US Breast Cancer Therapy Market Overview
US Breast Cancer Drug Clinical Pipeline by Company & Phase
US Breast Cancer Drug Clinical Pipeline: 251 Drugs
Majority Drugs in Phase-II Trials: 73 Drugs
Marketed Breast Cancer Drugs in US: 32 Drugs
Breast Cancer Patent Analysis
Breast Cancer in Young Women and its Impact on Reproductive FunctionApollo Hospitals
Breast cancer is the most common cancer in women in developed countries. Chemotherapy for breast cancer is likely to negatively impact on reproductive function. We review current treatment; effects on reproductive function; breastfeeding and management of menopausal symptoms following breast cancer.
Cancer genetic testing and risk assessment overview.
This slide deck was the basis of a presentation to nurse practitioners and genetic counselors who are actively identifying and managing women at high risk of breast and ovarian cancer.
Breast cancer develops from cells in the breast, usually in the lobules or ducts, and can invade nearby healthy tissue and lymph nodes over time. The most common types are ductal carcinoma, which starts in the ducts, and lobular carcinoma, which starts in the lobes. Breast cancer is staged based on tumor size and spread, from Stage 0 (non-invasive) to Stage IV (metastasized to other parts of the body). Risk factors include family history, genetic factors like BRCA1/2 mutations, reproductive factors, and lifestyle factors. Treatment depends on the cancer type and stage, and may involve surgery, radiation, chemotherapy, hormone therapy, and targeted biotherapies.
Using a prospective cohort study, researchers collected standard risk information and buccal swab samples from 783 women undergoing screening mammography to analyze 12 breast cancer-associated SNPs. They found that adding SNP information to traditional risk models reclassified some women's high risk status, particularly for Black women. For 11 of the 12 SNPs, Black women's allelic frequencies significantly differed from prior studies. Further research is needed on the clinical validity and utility of reclassifying breast cancer risk with SNP data.
This document summarizes breast cancer risks from both personal and environmental factors. It discusses how genetics and the environment can contribute to increased breast cancer risk and identifies some preventive measures. The key points are:
1) Breast cancer risk is influenced by a combination of personal factors like family history, age of first period, and hormone exposure, as well as environmental exposures.
2) Inherited genetic mutations account for 5-10% of cases, while genes like BRCA1 and BRCA2 cause 2-5% of cases.
3) Environmental toxins can damage breast DNA over time and increase cancer risk, while a healthy lifestyle with exercise, diet, weight control, and limiting alcohol can help reduce
This document discusses hereditary breast and ovarian cancer syndrome, which is caused by mutations in the BRCA1 and BRCA2 genes. Carriers of these mutations have significantly increased risks of developing breast cancer and ovarian cancer. The document provides estimates of cancer risks associated with BRCA1 and BRCA2 mutations and discusses clinical management recommendations, including who should be referred for genetic counseling and testing. Genetic counseling is important to discuss test results, cancer risks, and risk reduction options like increased screening and preventative surgeries.
BRCA – IMPORTANCE IN HEREDITARY BREAST & OVARIAN CANCER by Dr Sharda Jain Lifecare Centre
BRCA1 and BRCA2 gene mutations significantly increase the risks of breast and ovarian cancers. Screening for these mutations allows for increased surveillance and risk-reducing procedures that can improve health outcomes. Specifically:
- BRCA1/2 mutation carriers have a 40-80% risk of developing breast cancer and a 11-40% risk of ovarian cancer.
- Bilateral risk-reducing mastectomy can decrease breast cancer risk by at least 90% for carriers. Bilateral risk-reducing salpingo-oophorectomy can reduce ovarian and breast cancer risks by approximately 80% and 50% respectively.
- Genetic testing costs around 23k in India and allows high-risk families and individuals to
This document discusses genetic testing guidelines for breast and ovarian cancer. It provides an overview of current guidelines from organizations like USPSTF, NCCN, ACOG, and NICE. The USPSTF recommends testing only for those with a suggestive family history. NCCN guidelines provide more detailed criteria for testing breast cancer patients. Studies have found a high percentage (around 10%) of Ashkenazi Jewish women with breast cancer carry BRCA mutations, suggesting all such women should undergo genetic testing. Overall, the guidelines are evolving to expand testing to more patients as the therapeutic implications of mutations are better understood.
This document describes a breast cancer screening technology called the Mammary Aspirate Specimen Cytology Test (MASCT) developed by Atossa Genetics. The MASCT uses a reusable device to non-invasively collect nipple aspirate fluid, which contains cells that can be analyzed to detect pre-cancerous changes up to 8 years before mammography. The company plans to launch the MASCT product and an accompanying cytology analysis service in breast clinics across the US to tap into the $13 billion annual breast cancer screening market. Management aims to improve the technology and expand the types of molecular biomarkers analyzed over time to further advance breast cancer risk assessment.
Report Back from ASCO on Metastatic Breast Cancerbkling
Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, shares her experiences from the American Society of Clinical Oncology's June 2017 Conference. She also updates us on the latest research from the conference as it relates to metastatic breast cancer.
Cancer risk assessment is a multi-step process that involves taking a detailed family history, assessing individual risk levels, providing counseling and follow-up, and offering genetic testing when appropriate. Key factors that increase the likelihood of harmful BRCA1/2 mutations include early-onset breast or ovarian cancer, bilateral breast cancer, or a family history of both breast and ovarian cancer. For those found to carry a BRCA mutation, risk-reducing options like prophylactic surgeries, chemoprevention, and increased screening can help lower cancer risk. While genetic discrimination by life insurers has been a concern, recent studies found little evidence of this occurring after genetic counseling.
BRCA – Importance in Hereditary Breast & Ovarian CancerLifecare Centre
BRCA – Importance in Hereditary
Breast & Ovarian Cancer
DGF & WOW India
presentation was made by
Dr Sharda Jain
based on presentation made by
Dr Sunil Tadepalli
Breast cancer is the most common cancer among American women (American Cancer Society), but only 5-10 percent of breast cancer cases are hereditary. Of those cases, roughly 20-25 percent are linked to mutations in the BRCA1 and BRCA2 genes (BRCA stands for BReast CAncer susceptibility). View the infographic above for more on the genetics of breast cancer.
For more information on breast cancer, visit the website for Dana-Farber’s Susan F. Smith Center for Women’s Cancers Breast Oncology Program: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Breast-Cancer.aspx
It describes the prevalence of Breast Cancer among BRCA 1/2 mutations with special consideration to biological background, detection and screening, actions taken upon discovering mutation carriers and whether we have a different therapeutic algorithm than sporadic cases. Special emphasis on the role of PARP inhibitors in the management of metastatic disease.
The document summarizes information about hereditary breast and ovarian cancer syndrome (HBOC). It finds that 10-25% of breast cancer and 5-10% of ovarian cancer is considered hereditary. The majority of HBOC cases, around 84%, are caused by mutations in the BRCA1 and BRCA2 genes. Carriers of BRCA1 and BRCA2 mutations have significantly increased lifetime risks of developing breast cancer (56-87% for both genes) and ovarian cancer (44% for BRCA1, 27% for BRCA2) compared to the general population. Genetic testing for BRCA1 and BRCA2 mutations is available to assess cancer risk and guide risk-reducing medical or
Federal Research & Development for the Florida system Sept 2014 Warren Kibbe
This document discusses challenges in cancer data integration and analysis. It proposes the development of open science models, standardized data elements, and sustainable informatics infrastructure. Emerging technologies like mobile devices, social media, and cloud computing create opportunities to build a national "learning health system" for cancer. The National Cancer Institute is pursuing initiatives like the Cancer Genomics Data Commons and cloud pilots to leverage large genomic and clinical datasets using these technologies and develop predictive models to improve outcomes. The ultimate goal is a system that facilitates data sharing, continuous learning from all cancer patients, and personalized, predictive oncology.
The Risk Clinic Module is designed to manage the data and the workflow of a Breast/Ovarian Cancer High Risk Clinic. It is currently under modification to increase its utility for other Hereditary Clinics, such as Cardiac Disease or Colon Cancer. A set of screenshots and an overview of the module can be reviewed via this downloadable PowerPoint presentation.
The Risk Clinic Module is designed to manage the data and the workflow of a Breast/Ovarian Cancer High Risk Clinic. It is currently under modification to increase its utility for other Hereditary Clinics, such as Cardiac Disease or Colon Cancer. A set of screenshots and an overview of the module can be reviewed via this downloadable PowerPoint presentation.
Alterations of the genes involved in the PI3K and estrogen-receptor pathways ...Enrique Moreno Gonzalez
Chemotherapy with trastuzumab is widely used for patients with human epidermal growth
factor receptor 2-positive (HER2+) breast cancer, but a significant number of patients with
the tumor fail to respond, or relapse. The mechanisms of recurrence and biomarkers that indicate the response to the chemotherapy and outcome are not fully investigated.
Us breast cancer therapy market opportunity analysisKuicK Research
"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:
US Breast Cancer Incidence & Prevalence
US Breast Cancer Therapy Market Overview
US Breast Cancer Drug Clinical Pipeline by Company & Phase
US Breast Cancer Drug Clinical Pipeline: 251 Drugs
Majority Drugs in Phase-II Trials: 73 Drugs
Marketed Breast Cancer Drugs in US: 32 Drugs
Breast Cancer Patent Analysis
Breast Cancer in Young Women and its Impact on Reproductive FunctionApollo Hospitals
Breast cancer is the most common cancer in women in developed countries. Chemotherapy for breast cancer is likely to negatively impact on reproductive function. We review current treatment; effects on reproductive function; breastfeeding and management of menopausal symptoms following breast cancer.
Cancer genetic testing and risk assessment overview.
This slide deck was the basis of a presentation to nurse practitioners and genetic counselors who are actively identifying and managing women at high risk of breast and ovarian cancer.
Breast cancer develops from cells in the breast, usually in the lobules or ducts, and can invade nearby healthy tissue and lymph nodes over time. The most common types are ductal carcinoma, which starts in the ducts, and lobular carcinoma, which starts in the lobes. Breast cancer is staged based on tumor size and spread, from Stage 0 (non-invasive) to Stage IV (metastasized to other parts of the body). Risk factors include family history, genetic factors like BRCA1/2 mutations, reproductive factors, and lifestyle factors. Treatment depends on the cancer type and stage, and may involve surgery, radiation, chemotherapy, hormone therapy, and targeted biotherapies.
Using a prospective cohort study, researchers collected standard risk information and buccal swab samples from 783 women undergoing screening mammography to analyze 12 breast cancer-associated SNPs. They found that adding SNP information to traditional risk models reclassified some women's high risk status, particularly for Black women. For 11 of the 12 SNPs, Black women's allelic frequencies significantly differed from prior studies. Further research is needed on the clinical validity and utility of reclassifying breast cancer risk with SNP data.
This document summarizes breast cancer risks from both personal and environmental factors. It discusses how genetics and the environment can contribute to increased breast cancer risk and identifies some preventive measures. The key points are:
1) Breast cancer risk is influenced by a combination of personal factors like family history, age of first period, and hormone exposure, as well as environmental exposures.
2) Inherited genetic mutations account for 5-10% of cases, while genes like BRCA1 and BRCA2 cause 2-5% of cases.
3) Environmental toxins can damage breast DNA over time and increase cancer risk, while a healthy lifestyle with exercise, diet, weight control, and limiting alcohol can help reduce
This document discusses hereditary breast and ovarian cancer syndrome, which is caused by mutations in the BRCA1 and BRCA2 genes. Carriers of these mutations have significantly increased risks of developing breast cancer and ovarian cancer. The document provides estimates of cancer risks associated with BRCA1 and BRCA2 mutations and discusses clinical management recommendations, including who should be referred for genetic counseling and testing. Genetic counseling is important to discuss test results, cancer risks, and risk reduction options like increased screening and preventative surgeries.
BRCA – IMPORTANCE IN HEREDITARY BREAST & OVARIAN CANCER by Dr Sharda Jain Lifecare Centre
BRCA1 and BRCA2 gene mutations significantly increase the risks of breast and ovarian cancers. Screening for these mutations allows for increased surveillance and risk-reducing procedures that can improve health outcomes. Specifically:
- BRCA1/2 mutation carriers have a 40-80% risk of developing breast cancer and a 11-40% risk of ovarian cancer.
- Bilateral risk-reducing mastectomy can decrease breast cancer risk by at least 90% for carriers. Bilateral risk-reducing salpingo-oophorectomy can reduce ovarian and breast cancer risks by approximately 80% and 50% respectively.
- Genetic testing costs around 23k in India and allows high-risk families and individuals to
This document discusses genetic testing guidelines for breast and ovarian cancer. It provides an overview of current guidelines from organizations like USPSTF, NCCN, ACOG, and NICE. The USPSTF recommends testing only for those with a suggestive family history. NCCN guidelines provide more detailed criteria for testing breast cancer patients. Studies have found a high percentage (around 10%) of Ashkenazi Jewish women with breast cancer carry BRCA mutations, suggesting all such women should undergo genetic testing. Overall, the guidelines are evolving to expand testing to more patients as the therapeutic implications of mutations are better understood.
This document describes a breast cancer screening technology called the Mammary Aspirate Specimen Cytology Test (MASCT) developed by Atossa Genetics. The MASCT uses a reusable device to non-invasively collect nipple aspirate fluid, which contains cells that can be analyzed to detect pre-cancerous changes up to 8 years before mammography. The company plans to launch the MASCT product and an accompanying cytology analysis service in breast clinics across the US to tap into the $13 billion annual breast cancer screening market. Management aims to improve the technology and expand the types of molecular biomarkers analyzed over time to further advance breast cancer risk assessment.
Report Back from ASCO on Metastatic Breast Cancerbkling
Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, shares her experiences from the American Society of Clinical Oncology's June 2017 Conference. She also updates us on the latest research from the conference as it relates to metastatic breast cancer.
Cancer risk assessment is a multi-step process that involves taking a detailed family history, assessing individual risk levels, providing counseling and follow-up, and offering genetic testing when appropriate. Key factors that increase the likelihood of harmful BRCA1/2 mutations include early-onset breast or ovarian cancer, bilateral breast cancer, or a family history of both breast and ovarian cancer. For those found to carry a BRCA mutation, risk-reducing options like prophylactic surgeries, chemoprevention, and increased screening can help lower cancer risk. While genetic discrimination by life insurers has been a concern, recent studies found little evidence of this occurring after genetic counseling.
BRCA – Importance in Hereditary Breast & Ovarian CancerLifecare Centre
BRCA – Importance in Hereditary
Breast & Ovarian Cancer
DGF & WOW India
presentation was made by
Dr Sharda Jain
based on presentation made by
Dr Sunil Tadepalli
Breast cancer is the most common cancer among American women (American Cancer Society), but only 5-10 percent of breast cancer cases are hereditary. Of those cases, roughly 20-25 percent are linked to mutations in the BRCA1 and BRCA2 genes (BRCA stands for BReast CAncer susceptibility). View the infographic above for more on the genetics of breast cancer.
For more information on breast cancer, visit the website for Dana-Farber’s Susan F. Smith Center for Women’s Cancers Breast Oncology Program: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Breast-Cancer.aspx
It describes the prevalence of Breast Cancer among BRCA 1/2 mutations with special consideration to biological background, detection and screening, actions taken upon discovering mutation carriers and whether we have a different therapeutic algorithm than sporadic cases. Special emphasis on the role of PARP inhibitors in the management of metastatic disease.
The document summarizes information about hereditary breast and ovarian cancer syndrome (HBOC). It finds that 10-25% of breast cancer and 5-10% of ovarian cancer is considered hereditary. The majority of HBOC cases, around 84%, are caused by mutations in the BRCA1 and BRCA2 genes. Carriers of BRCA1 and BRCA2 mutations have significantly increased lifetime risks of developing breast cancer (56-87% for both genes) and ovarian cancer (44% for BRCA1, 27% for BRCA2) compared to the general population. Genetic testing for BRCA1 and BRCA2 mutations is available to assess cancer risk and guide risk-reducing medical or
Federal Research & Development for the Florida system Sept 2014 Warren Kibbe
This document discusses challenges in cancer data integration and analysis. It proposes the development of open science models, standardized data elements, and sustainable informatics infrastructure. Emerging technologies like mobile devices, social media, and cloud computing create opportunities to build a national "learning health system" for cancer. The National Cancer Institute is pursuing initiatives like the Cancer Genomics Data Commons and cloud pilots to leverage large genomic and clinical datasets using these technologies and develop predictive models to improve outcomes. The ultimate goal is a system that facilitates data sharing, continuous learning from all cancer patients, and personalized, predictive oncology.
The Risk Clinic Module is designed to manage the data and the workflow of a Breast/Ovarian Cancer High Risk Clinic. It is currently under modification to increase its utility for other Hereditary Clinics, such as Cardiac Disease or Colon Cancer. A set of screenshots and an overview of the module can be reviewed via this downloadable PowerPoint presentation.
The Risk Clinic Module is designed to manage the data and the workflow of a Breast/Ovarian Cancer High Risk Clinic. It is currently under modification to increase its utility for other Hereditary Clinics, such as Cardiac Disease or Colon Cancer. A set of screenshots and an overview of the module can be reviewed via this downloadable PowerPoint presentation.
The document provides an overview of genomics in breast cancer and summarizes the Oncotype DX genomic assay. It discusses how the assay analyzes the expression levels of 21 genes in breast tumor tissue to provide a Recurrence Score that quantifies a patient's risk of recurrence and predicts who will benefit from chemotherapy. Clinical studies have shown the assay stratifies patients into low, intermediate, and high risk groups and identifies those unlikely to benefit from chemotherapy while high risk patients see significant reduction in recurrence with chemotherapy. The assay is recommended in clinical guidelines and widely covered by insurance.
This document discusses prevention of breast and cervical cancer in women. It covers leading causes of death for women, risk factors, screening methods, symptoms, and preventive measures. The key points are:
1) Heart disease, cancer, and stroke are the top three leading causes of death for women. Cancer screening and treatments have improved survival rates to 66% for people diagnosed between 1966-2002.
2) Risk factors for cancer include age, family history, lifestyle factors like smoking, and genetic conditions. Screening methods include self-exams, clinical exams, mammography, and HPV testing to detect cancers early.
3) Preventive measures include vaccinations, safe sexual practices, smoking cessation, healthy
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Learn more at GENETechinfo.com.
There are a variety of tests that you may face during the process of your diagnosis which will likely affect your treatment decision making. Join this informative webinar where Scott Weissman, MS, CGC, will explain the difference between tumor and germline testing so that you can better understand the tests you receive and what they mean for you.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
This document provides an overview of breast cancer genetics and risk assessment. It discusses that 10-25% of cancers are hereditary while the majority are due to acquired mutations over a lifetime. Highly penetrant genes like BRCA1 and BRCA2 confer large risks, while many low penetrance genes each confer small risks. Risk assessment evaluates family history and can classify risk as average, moderate or high to guide screening and management. Genetic testing of high risk families can identify pathogenic variants to further guide screening and prevention for mutation carriers and their relatives.
Cancer genetic counseling services provide important benefits for those with and without cancer. Genetic counselors educate patients about their cancer risks, help patients understand genetic testing results, and empower informed decision making. While genetic testing identifies only a small percentage of cancer cases, it allows for targeted treatment and screening that can prevent cancer in families. Expanding access to genetic risk assessment and counseling could help identify more high-risk individuals and families earlier to reduce cancer burden through prevention and early detection strategies.
Performance and Evaluation of Data Mining Techniques in Cancer DiagnosisIOSR Journals
Abstract: We analyze the breast Cancer data available from the WBC, WDBC from UCI machine learning with
the aim of developing accurate prediction models for breast cancer using data mining techniques. Data mining
has, for good reason, recently attracted a lot of attention, it is a new Technology, tackling new problem, with
great potential for valuable commercial and scientific discoveries. The experiments are conducted in WEKA.
Several data mining classification techniques were used on the proposed data. There are many classification
techniques in data mining such as Decision Tree, Rules NNge, Tree random forest, Random Tree, lazy IBK. The
aim of this paper is to investigate the performance of different classification techniques. The data breast cancer
data with a total 286 rows and 10 columns will be used to test and justify the different between the classification
methods and algorithm.
Keywords - Machine learning, data mining Weka, classification, breast cancer
In this webinar, Fight CRC Medical Advisory Board member, Heather Hampel, MS, LGC, will discuss the major sub-types of hereditary colon cancer, the types of genetic tests that by be useful for you and your family, and what to do with your test results.
Screening modalities like the Pap test and HPV test can help detect abnormal or precancerous cervical cells. The Pap test screens for cell changes and is recommended starting at age 21 and every 3 years. The HPV test screens specifically for the human papillomavirus, which can cause cell changes. For women over 30, both tests may be used. Certain groups like those without insurance can access free screening services. While screening is important, both false positives and false negatives can occur with the Pap test. Multiple organizations provide guidelines around cervical cancer screening.
Screening modalities like the Pap test and HPV test can help detect abnormal or precancerous cervical cells. The Pap test screens for cell changes and is recommended starting at age 21 and every 3 years. The HPV test screens specifically for the human papillomavirus, which can cause cell changes. For women over 30, both tests may be used. Certain groups are at higher risk for cervical cancer, including those with lower incomes or HIV/AIDS. While screening can help detect cell changes, both tests can produce false positives or negatives, so guidelines recommend less frequent screening to avoid unnecessary procedures. Treatment options depend on age and test results but aim to remove visible warts or abnormal cells.
When Cells Go Rogue and Become Breast Cancerbkling
Let's have a conversation about our bodies and learn about the why's and how healthy cells mutate into cancer. Diva Whalen, Ph.D., Assistant Professor & Pre Health Advisor in Biology at Tougaloo College, will discuss how our genetics, where we live, and stress can be major factors in how breast cancer forms, what happens once diagnosed, and recurrence risks, especially in communities of color. Understand the importance of knowing what is "normal" for your body before, during, and after treatment.
A Review on Data Mining Techniques for Prediction of Breast Cancer RecurrenceDr. Amarjeet Singh
The most common type of cancer in women
worldwide is the Breast Cancer. Breast cancer may be
detected early using Mammograms, probably before it's
spread. Recurrent breast cancer could occur months or years
after initial treatment. The cancer could return within the
same place because the original cancer (local recurrence), or it
may spread to different areas of your body (distant
recurrence). Early stage treatment is done not only to cure
breast cancer however additionally facilitate in preventing its
repetition/recurrence. Data mining algorithms provide
assistance in predicting the early-stage breast cancer that
continually has been difficult analysis drawback. The
projected analysis can establish the most effective algorithm
that predicts the recurrence of the breast cancer and improve
the accuracy the algorithms. Large information like Clump,
Classification, Association Rules, Prediction and Neural
Networks, Decision Trees can be analyzed using data mining
applications and techniques.
This document discusses using machine learning for breast cancer detection. It begins with an introduction on breast cancer prevalence and existing machine learning methods. It then discusses breast cancer conditions in India, noting rising case numbers. Key factors in late diagnosis are identified as lack of awareness programs and low participation. The proposed methodology uses CNN for automated feature extraction to distinguish malignant from benign tumors faster. It describes preprocessing, augmentation, model testing and accuracy evaluation. Risk factors, signs, and prevention strategies are outlined. A schematic diagram and steps of the detection process are provided. The conclusion notes high accuracy achieved and potential for early detection to improve outcomes.
Screening modalities like the Pap test and HPV test can help detect abnormal or precancerous cervical cells. The Pap test screens for cell changes and is recommended starting at age 21 and every 3 years. The HPV test screens specifically for the human papillomavirus, which can cause cell changes. For women over 30, both tests may be used. Certain groups like those without insurance can access free screening services. While screening is important, both false positives and false negatives can occur with the Pap test. Multiple organizations provide guidelines around cervical cancer screening.
Screening modalities like the Pap test and HPV test can help detect abnormal or precancerous cervical cells. The Pap test screens for cell changes and is recommended starting at age 21 and every 3 years. The HPV test screens specifically for the human papillomavirus, which can cause cell changes. For women over 30, both tests may be used. Certain groups like those without insurance can access free screening services. While screening is important, both false positives and false negatives can occur with the Pap test. Multiple organizations provide guidelines around cervical cancer screening.
Similar to Analysis of the breast cancer (familial) (20)
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
1. Analysis of the Breast Cancer
(Familial) Gene and Disease
Association
By: Crystal Thomas
2. What is Breast Cancer?
• Breast cancer is a type of cancer
that affects the breast region.
• It is said to be affecting one in eight
women and being one of the
leading causes of death in women
in the United States (Medline Plus,
2015).
• Even though it is popular in
women, men may also suffer from
breast cancer in rare cases
(National Cancer Institute, 2015).
3. Risks
• Gender (Women more often
than men)
• Age
• Race
• Dense breast tissue
• Family history
• Genetics
(American Cancer Society, 2015).
4. Genetics
• Approximately 5% to 10% of
breast cancers are said to be
caused by family genes passed
on to their children, hence
familial breast cancer (Beast
Cancer.org, 2015).
5. Genetics (Continuted)
• Familial breast cancer contain
several genes that may have
caused breast cancer formation
in people such as: BRCA1,
BRCA2, ATM, TP53, CHEK2,
PTEN, CDH1, PALB2, RINT1,
RAD50, and NBN (Breast
Cancer.org, 2015).
• Those abnormal genes may also
be present in other diseases as
well.
6. Genetics (Continued
• PTEN: cancer of digestive tract,
thyroid, uterus, and ovaries
• CDH1: stomach cancer
• BRCA1 and BRCA2: ovarian
cancer and other cancers
• NBN: Nijmegen Breakage
Syndrome (slow growth during
infancy and childhood)
(Breast Cancer.org, 2015)
7. Hypothesis
• Discovering this has led me to formulate my hypothesis: people with
diseases that have highest amounts of familial breast cancer disease
genes would be more susceptible to having familial breast cancer.
8. DisGeNet
• I was able to collect data for the
familial breast cancer genes and
disease association by utilizing
DisGeNet, a database that would
incorporate information on
gene-disease association
through public data and
literature sources (Pinero et al.,
2015).
9. DisGeNet (Continued)
• DisGeNet has overall 381056
disease and gene associations
(16666 genes and 13172 diseases)
(Pinero et al., 2015).
• Since the number of disease and
gene associations are relatively
high, DisGeNet created a score “in
order to rank the associations
based on the supporting evidence”
(Pinero et al., 2015).
• This database can be examined by
using Browse and Search queries
(Pinero et al., 2015).
10. DisGeNet (Continued)
• In order for me to gather data, I
used the Search query on the
website and selected the
diseases button to type the
specific disease name (Breast
Cancer, Familial).
(DisGeNET Database, 2015)
11. DisGeNet (Continued)
• I have chosen three types of data to work with for my analysis: All
Diseases that Share Genes, Summary of Disease that Share Genes,
and Summary of Associated Genes.
15. Excel
• All three data were exported to
Microsoft’s Excel program in
order for me to perform data
manipulations to determine the
validity of my hypothesis.
16. Excel (Continued)
• Since the data contained 3,609
different diseases that contained
familial breast cancer genes, I
decided to create a pivot table
to portray the top 25 diseases
that shared those genes and the
total number of genes that were
included.
• *The table portrayed 26
different diseases since the final
two diseases have the same
number of genes.*
Disease Names Sum of Number Of Shared Genes
Malignant neoplasm breast 107
Breast Carcinoma 105
NEOPLASM MALIGNANT 101
Carcinoma 83
Breast Neoplasms 78
Malignant neoplasm of prostate 76
OVARIAN CARCINOMA 74
Malignant neoplasm of ovary 73
Colorectal Cancer 72
prostate carcinoma 72
Neoplasms 70
Carcinogenesis 70
MALIGNANT LUNG NEOPLASM 67
Neoplasm Metastasis 66
Colorectal Carcinoma 64
Carcinoma, Hepatocellular 62
Melanoma 61
Malignant neoplasm of bladder 60
Carcinoma, Non-Small-Cell Lung 59
Metastatic Neoplasm 59
Adenocarcinoma 59
Ovarian epithelial cancer 58
Tumor Progression 58
Leukemia 57
Colorectal Neoplasms 55
Prostatic Neoplasms 55
Grand Total 1821
17. Summary of Associated Genes
• I was curious to see which
familial breast cancer gene has
the highest score and to see
which diseases were associated
with that particular gene.
• I found that the BRCA genes
(1&2) were the top Genes
according to DisGeNet’s score
and number of resources found
in Pubmed database.
18. Disease ID
• On Microsoft Access, my goal was to perform computations and
further manipulations built from work that I have performed using
Excel.
• The Number of Shared Genes Sorted worksheet was imported
through access to receive an ID number for the disease names.
19. Number of Shared Genes Sorted
Disease ID Disease Names Sum of Number Of Shared Genes
1 Malignant neoplasm breast 107
2 Breast Carcinoma 105
3 NEOPLASM MALIGNANT 101
4 Carcinoma 83
5 Breast Neoplasms 78
6 Malignant neoplasm of prostate 76
7 OVARIAN CARCINOMA 74
8 Malignant neoplasm of ovary 73
9 Colorectal Cancer 72
10 prostate carcinoma 72
11 Neoplasms 70
12 Carcinogenesis 70
13 MALIGNANT LUNG NEOPLASM 67
14 Neoplasm Metastasis 66
15 Colorectal Carcinoma 64
16 Carcinoma, Hepatocellular 62
17 Melanoma 61
18 Malignant neoplasm of bladder 60
19 Carcinoma, Non-Small-Cell Lung 59
20 Metastatic Neoplasm 59
21 Adenocarcinoma 59
22 Ovarian epithelial cancer 58
23 Tumor Progression 58
24 Leukemia 57
25 Colorectal Neoplasms 55
26 Prostatic Neoplasms 55
22. Relationships
• Gene and Bridge Tables were
imported into Access from Excel.
• In order to see whether or not
those tables were interrelated,
relationships were formed.
23. Query
• Since the tables are aware that
they are interrelated, it allowed
me to be able to create a query
to see whether or not I have
accurately integrated the
content from those tables.
24. Network Analysis
• In order to view familial breast
cancer gene-disease interaction,
I decided to perform a network
analysis with the top 25 diseases
and familial breast cancer genes
by using Pajek network tool.
26. 2 Degree Centrality
• I noticed that I have lost
one of the vertices, which
was the LHFP gene from
Neoplasm Malignant
disease. This means that
LHFP gene was the only
gene that has less than 2
degree centrality.
27. VOSviewer
• To provide another visualization
for this analysis, I decided to
import what I have done from
Pajek network program to
VOSviewer.
• The diseases and genes were
ranked according to color. Red
symbolizes the largest node (i.e.
Malignant Neoplasm Breast due
to having most amount of
familial breast cancer genes).
28. Results
• This table shows that malignant
neoplasm of breast (breast
cancer) has the most amount of
familial breast cancer genes out
of 3,609 diseases.
• According to American Cancer
Society (2015), if a person has
had breast cancer (or malignant
neoplasm of breast) in the past,
that person would have a
“greater chance of getting
another breast cancer.”
Disease Names Sum of Number Of Shared Genes
Malignant neoplasm breast 107
Breast Carcinoma 105
NEOPLASM MALIGNANT 101
Carcinoma 83
Breast Neoplasms 78
Malignant neoplasm of prostate 76
OVARIAN CARCINOMA 74
Malignant neoplasm of ovary 73
Colorectal Cancer 72
prostate carcinoma 72
Neoplasms 70
Carcinogenesis 70
MALIGNANT LUNG NEOPLASM 67
Neoplasm Metastasis 66
Colorectal Carcinoma 64
Carcinoma, Hepatocellular 62
Melanoma 61
Malignant neoplasm of bladder 60
Carcinoma, Non-Small-Cell Lung 59
Metastatic Neoplasm 59
Adenocarcinoma 59
Ovarian epithelial cancer 58
Tumor Progression 58
Leukemia 57
Colorectal Neoplasms 55
Prostatic Neoplasms 55
Grand Total 1821
(DisGeNet Database,
2015)
29. Results
• The table also revealed that all of
the top 25 diseases are cancer-
related.
• In regards to this result, Dr. Michael
Naughton of Washington School of
Medicine theory was “because the
body’s immune system was
vulnerable to the development of
the first cancer, it may be more
susceptible to the development of
a second cancer” (National
Comprehensive Cancer Network,
2015).
Disease Names Sum of Number Of Shared Genes
Malignant neoplasm breast 107
Breast Carcinoma 105
NEOPLASM MALIGNANT 101
Carcinoma 83
Breast Neoplasms 78
Malignant neoplasm of prostate 76
OVARIAN CARCINOMA 74
Malignant neoplasm of ovary 73
Colorectal Cancer 72
prostate carcinoma 72
Neoplasms 70
Carcinogenesis 70
MALIGNANT LUNG NEOPLASM 67
Neoplasm Metastasis 66
Colorectal Carcinoma 64
Carcinoma, Hepatocellular 62
Melanoma 61
Malignant neoplasm of bladder 60
Carcinoma, Non-Small-Cell Lung 59
Metastatic Neoplasm 59
Adenocarcinoma 59
Ovarian epithelial cancer 58
Tumor Progression 58
Leukemia 57
Colorectal Neoplasms 55
Prostatic Neoplasms 55
Grand Total 1821
(DisGeNet Database,
2015)
31. 0
20
40
60
80
100
120
Adenocarcinoma
Breast Carcinoma
Breast Neoplasms
Carcinogenesis
Carcinoma
Carcinoma, Hepatocellular
Carcinoma, Non-Small-Cell Lung
Colorectal Cancer
Colorectal Carcinoma
Colorectal Neoplasms
Leukemia
MALIGNANT LUNG NEOPLASM
Malignant neoplasm breastMalignant neoplasm of bladder
Malignant neoplasm of ovary
Malignant neoplasm of prostate
Melanoma
Metastatic Neoplasm
NEOPLASM MALIGNANT
Neoplasm Metastasis
Neoplasms
OVARIAN CARCINOMA
Ovarian epithelial cancer
prostate carcinoma
Tumor Progression
Number of Genes in Top 25 Diseases
(DisGeNet Database,
2015)
32. Results (Continued)
• According to the Initial_from_DisGeNet worksheet from Excel, there
were many diseases that were not within the top 25 that are
considered non-cancerous (i.e. Anorexia Nervosa (1 familial breast
cancer genes), Abdominal Obesity Metabolic Syndrome (1 familial
breast cancer genes), Cognition Disorder (1 familial breast cancer
genes), and a mental disorder Asperger’s Syndrome (1 familial breast
cancer genes).
34. • However, majority of the diseases were listed on that table were still
cancer-related. In regards to this result, Dr. Michael Naughton of
Washington School of Medicine theory was “because the body’s
immune system was vulnerable to the development of the first
cancer, it may be more susceptible to the development of a second
cancer” (National Comprehensive Cancer Network, 2015). This led
me to believe that specific genes that were involved in each disease
may increase one’s chance of suffering from familial breast cancer.
35. Results (continued)
• The results from Table 2 portray
the genes that have all of the top
25 diseases. The results network
analysis from Pajek network tool
showed that all of those genes
have the highest value of 26.
The lowest value was 1, the
LHFP gene, which was taken out
of the network due to it having a
degree of centrality less than 2.
Genes Number of Diseases
FHIT 26
PTEN 26
PCNA 26
PARP1 26
MYC 26
MDM2 26
ATM 26
IGF1 26
RASSF1 26
HIF1A 26
MLH1 26
ESR1 26
ERBB2 26
EGFR 26
CHEK2 26
CCND1 26
CASP8 26
BRCA2 26
BRCA1 26
HRAS 26
XRCC1 26
VEGFA 26
TP53 26
36. Conclusion
• The results of the analysis suggested that the diseases that have most
amount of familial breast cancer genes may cause one to be more
susceptible to having familial breast cancer. However, it also helped me to
develop another theory: there are some diseases on the initial list that are
not cancerous but may put someone at risk due to a specific gene with the
highest score according to DisGeNet Database. For instance, some
diseases, like obesity, may not be cancer-related, but it does have the
BRCA1 gene (and 41 other familial breast cancer genes) according to
DisGeNet’s database which I have found to be particularly shocking (shown
in the appendix section). One would have never thought that a disease
like obesity to have a gene that was particularly well-known for breast
cancer diagnosis. I believe that there needs to be more research regarding
this surprise discovery.
37. Conclusion (Continued)
• Ultimately, genes may only account for 5% to 10% of breast cancer
cases (American Cancer Society, 2015). When one decides to perform
research on genetic factors of breast cancer, they should be aware
that there are other risk factors to consider such as lifestyle and
environment, which may trigger the mutation of the familial breast
cancer genes. They also should take into consideration that if
someone has familial breast cancer genes or other risk factors, it does
not necessarily mean that they are guaranteed to suffer from such a
deadly disease sometime in their lives.
38. Works Cited
• American Cancer Society. (2015). What are the risk factors for breast cancer. Retrieved from:
http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors
• BreastCancer.Org. (2015). Genetics. Retrieved from: http://www.breastcancer.org/risk/factors/genetics
• Centers for Disease Control and Prevention. (2015). Cancer prevention. Retrieved from:
http://www.cdc.gov/cancer/dcpc/prevention/index.htm
• DisGeNET Database. (2015). All diseases that share genes [data file]. Available from www.disgenet.org
• DisGeNET Database. (2015). Summary of associated genes [data file]. Available from www.disgenet.org
• DisGeNET Database. (2015). Summary of disease that share genes [data file]. Available from www.disgenet.org
• MedlinePlus. (2015). Breast cancer. Retrieved from: http://www.nlm.nih.gov/medlineplus/breastcancer.html
• National Cancer Institute. (2015). BRCA1 and BRCA2: Cancer risk and genetic testing. Retrieved from:
http://www.cancer.gov/cancertopics/causes-prevention/genetics/brca-fact-sheet
• National Comprehensive Cancer Network. (2015). Understanding your risk of developing secondary cancers. Retrieved from:
http://www.nccn.org/patients/resources/life_after_cancer/understanding.aspx
• Pinero, J. et al. (2015). DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database
(2015) Vol. 2015: article ID bav028; doi:10.1093/database/bav028